CSA Medical, Inc. develops and manufactures the RejuvenAir System, a proprietary interventional liquid nitrogen spray cryotherapy system that utilizes software-driven dosimetry and specialty catheters to enable delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells allowing for a rejuvenative pattern of healing. The RejuvenAir System is approved in the EU and under clinical investigation in the United States. To learn more about our technology or clinical trials, please visit www.rejuvenair.com or www.clinicaltrials.gov [Identifiers: NCT03893370 and NCT03892694].